Wagner, Lars M <br/><br/>
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.  [electronic resource] 

 -  Pediatric blood & cancer  Apr 2010 
 - 538-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.22407  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics<br/>Area Under Curve<br/>Camptothecin--administration & dosage<br/>Child<br/>Child, Preschool<br/>Dacarbazine--administration & dosage<br/>Female<br/>Humans<br/>Infant<br/>Irinotecan<br/>Male<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasms--drug therapy<br/>Temozolomide<br/>Vincristine--administration & dosage<br/>Young Adult